{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:56:23Z","timestamp":1760147783150,"version":"build-2065373602"},"reference-count":69,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Along with the fact that classical Hodgkin lymphoma (cHL) in older adults is frequently considered biologically different from cHL in younger patients, its most distinctive feature is its dismal clinical outcome due to the decreased effectiveness and greater toxicity of therapies. Although strategies to mitigate specific toxicities (e.g., cardiological and pulmonary) have obtained some results, in general, reduced-intensity schemes, proposed as an alternative to ABVD, have proved to be less effective. The addition of brentuximab vedotin (BV) to AVD, especially in a sequential scheme, has demonstrated good efficacy. However, the problem of toxicity persists even with this new therapeutic combination, with comorbidities remaining an important prognostic factor. The adequate stratification of functional status is necessary to distinguish between those patients who will benefit from full treatment and those who will benefit from alternative strategies. A simplified geriatric assessment based on the determination of ADL (activity of daily living), IADL (instrumental ADL), and CIRS-G (Cumulative Illness Rating Scale\u2014Geriatric) scores is an easy-to-use tool that permits adequate patient stratification. Other factors of considerable impact on functional status such as sarcopenia and immunosenescence are currently being studied. A fitness-based treatment choice would also be very useful for relapsed or refractory patients, a more frequent and challenging situation than that is found in young cHL patients.<\/jats:p>","DOI":"10.3390\/cancers15051515","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T03:00:38Z","timestamp":1677553238000},"page":"1515","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-2246","authenticated-orcid":false,"given":"Vittorio Ruggero","family":"Zilioli","sequence":"first","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Muzi","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pagani","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Ravano","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Meli","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Daffini","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ravelli","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-2623","authenticated-orcid":false,"given":"Roberto","family":"Cairoli","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-6395","authenticated-orcid":false,"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2014050","DOI":"10.4084\/mjhid.2014.050","article-title":"Hodgkin\u2019s lymphoma in older patients: An orphan disease?","volume":"6","author":"Thyss","year":"2014","journal-title":"Mediterr J. Hematol. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: A population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2018.1522435","article-title":"Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: A national cancer data base analysis","volume":"60","author":"Major","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2128373","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of Treatment Intensity with Survival in Older Patients with Hodgkin Lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X","article-title":"Hodgkin disease in the elderly. A registry-based analysis","volume":"70","author":"Erdkamp","year":"1992","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin\u2019s disease in patients above the age of 60: A population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CCO.0b013e328348c6c1","article-title":"How we treat elderly patients with Hodgkin lymphoma","volume":"23","author":"Svedmyr","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/13.S1.23","article-title":"Viruses and Hodgkin\u2019s lymphoma","volume":"13","author":"Jarrett","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2008.20.5138","article-title":"Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin\u2019s lymphoma predicts adverse outcome in older adult patients","volume":"27","author":"Diepstra","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41375-020-0875-0","article-title":"Primary therapy and relative survival in classical Hodgkin lymphoma: A nationwide population-based study in the Netherlands, 1989\u20132017","volume":"35","author":"Driessen","year":"2021","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","article-title":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma","volume":"11","author":"Thomas","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"Fuchs","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Isaac","year":"2021","journal-title":"Blood Adv."},{"key":"ref_20","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: The SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"Bredenfeld","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13904","article-title":"Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)","volume":"172","author":"Zallio","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2019.1608529","article-title":"Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (\u226570 years) or cardiopathic patients with Hodgkin lymphoma: A phase-II study from Fondazione Italiana Linfomi (FIL)","volume":"60","author":"Salvi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: Frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.HS9.0000890896.83681.49","article-title":"AVD\u2013A possible golden standard in the firstline treatment of older classical Hodgkin lymphoma patients","volume":"6","author":"Overgaard","year":"2022","journal-title":"Hemasphere"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u2265 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_33","unstructured":"(2017). Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, U.S. Department of Health and Human Services."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fogg, C., Fraser, S.D.S., Roderick, P., de Lusignan, S., Clegg, A., Brailsford, S., Barkham, A., Patel, H.P., Windle, V., and Harris, S. (2022). The dynamics of frailty development and progression in older adults in primary care in England (2006\u20132017): A retrospective cohort profile. BMC Geriatr., 22.","DOI":"10.1186\/s12877-021-02684-y"},{"key":"ref_35","unstructured":"(2023, January 15). 2021 Life Expectancy Table -New York State Department of Health, Available online: https:\/\/www.health.ny.gov\/health_care\/medicaid\/publications\/docs\/gis\/21ma19_att1.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: Self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the Cumulative Illness Rating Scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified Geriatric Assessment in Older Patients with Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","article-title":"A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL","volume":"5","author":"Isaksen","year":"2021","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_42","unstructured":"National Library of Medicine (U.S.) (2023, January 15). Prospective Study on Elderly (_65 Years) Patients Affected with Classical Hodgkin Lymphoma Undergoing Comprehensive Geriatric Assessment at Diagnosis, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03552003."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00198-009-1059-y","article-title":"Sarcopenia: Etiology, clinical consequences, intervention, and assessment","volume":"21","author":"Lang","year":"2010","journal-title":"Osteoporos Int."},{"key":"ref_44","first-page":"412","article-title":"European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Baeyens","year":"2010","journal-title":"Age Ageing"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.24465","article-title":"Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy","volume":"91","author":"Xiao","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/10428194.2013.816421","article-title":"Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"55","author":"Lanic","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00277-015-2499-4","article-title":"Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma","volume":"94","author":"Nakamura","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jcsm.12115","article-title":"Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"7","author":"Go","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcsm.12161","article-title":"Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy","volume":"8","author":"Chu","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/jcsm.12736","article-title":"Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: A multicentre experience","volume":"12","author":"Zilioli","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2016.142810","article-title":"SWG \u201cAging and Hematology\u201d of the EHA. Innovative approach to older patients with malignant hemopathies","volume":"101","author":"Bron","year":"2016","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-015-0457-x","article-title":"The biology of aging and lymphoma: A complex interplay","volume":"17","author":"Sarkozy","year":"2015","journal-title":"Curr. Oncol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Holkova","year":"2015","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): A multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: A comprehensive analysis from the German hodgkin study group","volume":"31","author":"Goergen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","article-title":"High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin\u2019s lymphoma","volume":"46","author":"Puig","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/bmt.2016.76","article-title":"Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin\u2019s lymphoma: A retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)","volume":"51","author":"Stamatoullas","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-016-2832-6","article-title":"Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in patients older than 50 years","volume":"96","author":"Jorge","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.12821","article-title":"Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: A retrospective study of the Fondazione Italiana Linfomi","volume":"166","author":"Anastasia","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.clml.2015.02.023","article-title":"Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin\u2019s lymphoma: Experience with 27 patients","volume":"15","author":"Zinzani","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3109\/10428194.2013.876496","article-title":"Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: A retrospective evaluation of safety and efficacy","volume":"55","author":"Gopal","year":"2014","journal-title":"Leuk. Lymphoma."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/5\/1515\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:43:51Z","timestamp":1760121831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/5\/1515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15051515"],"URL":"https:\/\/doi.org\/10.3390\/cancers15051515","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}